Market Closed -
Nyse
04:00:02 2024-05-03 pm EDT
|
5-day change
|
1st Jan Change
|
15.7
USD
|
+1.29%
|
|
+0.96%
|
-17.80%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
463.2
|
1,685
|
2,843
|
1,497
|
1,430
|
1,428
|
-
|
-
|
Enterprise Value (EV)
1 |
405.2
|
956.8
|
2,344
|
488.4
|
670.7
|
818
|
1,158
|
1,500
|
P/E ratio
|
-5.23
x
|
-11.6
x
|
57
x
|
-5.57
x
|
-4.6
x
|
-4.08
x
|
-3.67
x
|
-4.31
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
30.9
x
|
21.7
x
|
7.43
x
|
13.4
x
|
12.2
x
|
7.62
x
|
8.71
x
|
9
x
|
EV / Revenue
|
27
x
|
12.3
x
|
6.12
x
|
4.36
x
|
5.73
x
|
4.36
x
|
7.06
x
|
9.45
x
|
EV / EBITDA
|
-4.76
x
|
-7.9
x
|
40.3
x
|
-1.78
x
|
-2.02
x
|
-2.83
x
|
-2.94
x
|
-2.96
x
|
EV / FCF
|
-5.38
x
|
8.85
x
|
-8.3
x
|
1.13
x
|
-
|
-2.97
x
|
-3.83
x
|
-8.57
x
|
FCF Yield
|
-18.6%
|
11.3%
|
-12%
|
88.5%
|
-
|
-33.7%
|
-26.1%
|
-11.7%
|
Price to Book
|
-
|
-
|
-
|
2.29
x
|
3.12
x
|
3.21
x
|
-14.1
x
|
-
|
Nbr of stocks (in thousands)
|
45,859
|
64,923
|
70,249
|
72,408
|
74,856
|
90,953
|
-
|
-
|
Reference price
2 |
10.10
|
25.96
|
40.47
|
20.68
|
19.10
|
15.70
|
15.70
|
15.70
|
Announcement Date
|
3/5/20
|
2/24/21
|
2/23/22
|
2/28/23
|
2/21/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
15
|
77.52
|
382.9
|
112
|
117
|
187.4
|
164
|
158.7
|
EBITDA
1 |
-85.13
|
-121.1
|
58.09
|
-274
|
-332
|
-289
|
-393.4
|
-505.9
|
EBIT
1 |
-88.71
|
-124.2
|
54.25
|
-280
|
-340
|
-337.2
|
-416.7
|
-381.8
|
Operating Margin
|
-591.39%
|
-160.27%
|
14.17%
|
-250%
|
-290.6%
|
-179.92%
|
-254.06%
|
-240.54%
|
Earnings before Tax (EBT)
1 |
-84.71
|
-122.9
|
54.64
|
-266
|
-301
|
-338.1
|
-418.5
|
-357.2
|
Net income
1 |
-84.71
|
-122.9
|
52.83
|
-267
|
-307
|
-324.8
|
-381.8
|
-348.5
|
Net margin
|
-564.73%
|
-158.49%
|
13.8%
|
-238.39%
|
-262.39%
|
-173.32%
|
-232.82%
|
-219.56%
|
EPS
2 |
-1.930
|
-2.240
|
0.7100
|
-3.710
|
-4.150
|
-3.847
|
-4.273
|
-3.645
|
Free Cash Flow
1 |
-75.39
|
108.1
|
-282.2
|
432
|
-
|
-275.5
|
-302.5
|
-175
|
FCF margin
|
-502.58%
|
139.47%
|
-73.72%
|
385.71%
|
-
|
-146.99%
|
-184.45%
|
-110.26%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/5/20
|
2/24/21
|
2/23/22
|
2/28/23
|
2/21/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
9.461
|
354.5
|
18
|
26.76
|
33.58
|
34
|
25
|
29
|
32
|
31
|
28.77
|
30.06
|
30.2
|
29.49
|
27.36
|
EBITDA
1 |
-
|
-
|
-
|
-
|
-
|
-72.52
|
-
|
-
|
-
|
-88
|
-98.7
|
-99.74
|
-100.8
|
-101.9
|
-
|
EBIT
1 |
-78.14
|
281.3
|
-67.18
|
-68.98
|
-69.4
|
-74
|
-86
|
-83
|
-80
|
-91
|
-90.94
|
-92.35
|
-94.69
|
-95.55
|
-92
|
Operating Margin
|
-825.87%
|
79.34%
|
-373.12%
|
-257.79%
|
-206.66%
|
-217.65%
|
-344%
|
-286.21%
|
-250%
|
-293.55%
|
-316.04%
|
-307.21%
|
-313.52%
|
-324.02%
|
-336.26%
|
Earnings before Tax (EBT)
1 |
-77.98
|
281.2
|
-66.99
|
-66.63
|
-64.92
|
-67
|
-78
|
-74
|
-69
|
-80
|
-84.62
|
-84.87
|
-88.22
|
-90.72
|
-92
|
Net income
1 |
-77.98
|
279.4
|
-67.99
|
-66.63
|
-64.92
|
-67
|
-80
|
-75
|
-69
|
-81
|
-84.82
|
-85.07
|
-88.42
|
-90.92
|
-92
|
Net margin
|
-824.17%
|
78.81%
|
-377.63%
|
-249.01%
|
-193.32%
|
-197.06%
|
-320%
|
-258.62%
|
-215.62%
|
-261.29%
|
-294.78%
|
-282.99%
|
-292.77%
|
-308.31%
|
-336.26%
|
EPS
2 |
-1.110
|
3.710
|
-0.9600
|
-0.9300
|
-0.9000
|
-0.9300
|
-1.090
|
-1.040
|
-0.9400
|
-1.080
|
-0.9717
|
-0.9583
|
-0.9867
|
-1.020
|
-1.050
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/8/21
|
2/23/22
|
5/9/22
|
8/3/22
|
11/2/22
|
2/28/23
|
5/9/23
|
8/7/23
|
11/7/23
|
2/21/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
71.9
|
Net Cash position
1 |
57.9
|
729
|
499
|
1,009
|
759
|
610
|
270
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-0.142
x
|
Free Cash Flow
1 |
-75.4
|
108
|
-282
|
432
|
-
|
-276
|
-303
|
-175
|
ROE (net income / shareholders' equity)
|
-
|
-
|
7.86%
|
-35.6%
|
-54.9%
|
-58.1%
|
-201%
|
-118%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
2 |
-
|
-
|
-
|
9.010
|
6.120
|
4.890
|
-1.110
|
-
|
Cash Flow per Share
2 |
-
|
-
|
-
|
6.080
|
-4.140
|
1.500
|
-4.750
|
-
|
Capex
1 |
1.93
|
3.06
|
26.1
|
6
|
-
|
31
|
34
|
37.5
|
Capex / Sales
|
12.83%
|
3.94%
|
6.81%
|
5.36%
|
-
|
16.54%
|
20.73%
|
23.63%
|
Announcement Date
|
3/5/20
|
2/24/21
|
2/23/22
|
2/28/23
|
2/21/24
|
-
|
-
|
-
|
Last Close Price
15.7
USD Average target price
38.89
USD Spread / Average Target +147.70% Consensus |
1st Jan change
|
Capi.
|
---|
| -17.80% | 1.43B | | +25.69% | 47.86B | | +46.90% | 41.42B | | -3.46% | 40.66B | | -6.20% | 28.92B | | +9.17% | 25.55B | | -20.42% | 19.27B | | +0.17% | 12.15B | | +28.07% | 12.14B | | -1.24% | 11.99B |
Other Biotechnology & Medical Research
|